MaxCyte, Inc. (MXCT)

NASDAQHealth CareBiotechnologySnapshot 2026-09-04

$1.28+1.59%

Close 2026-09-04 · 1-day change

QuarterlyIQ Insights · MXCT

Financials

Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.

Income Statement

Period

View

Order

Figures in millions of None, except per-share and ratios.

	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenues
Revenues	31.1	33.0	38.6	41.3	44.3	33.9	26.2
Total Revenues	31.1	33.0	38.6	41.3	44.3	33.9	26.2
Cost of Revenues	6.5	6.2	7.1	4.7	5.1	3.6	2.8
Gross Profit	24.6	26.8	31.5	36.5	39.2	30.2	23.4
Operating Expenses & Income
R&D Expenses	16.8	20.8	22.2	23.8	19.5	15.4	17.7
Operating Income	(41.8)	(51.9)	(51.2)	(48.3)	(27.4)	(18.2)	(11.1)
Earnings from Continuing Operations
Interest Expense	—	—	—	—	—	0.0	0.0
Interest & Investment Income	6.2	7.3	10.1	10.4	3.9	0.2	0.1
Net Interest Expenses	—	—	—	—	—	(0.1)	(0.0)
EBT, Incl. Unusual Items	(35.6)	(44.6)	(41.1)	(37.9)	—	—	—
Income Tax Expense	—	—	—	—	—	0.0	0.0
Net Income
Net Income	(35.6)	(44.6)	(41.1)	(37.9)	(23.6)	(19.1)	(11.8)
Per Share
Basic EPS	(0.33)	(0.42)	(0.39)	(0.37)	(0.23)	(0.21)	(0.17)
Diluted EPS	(0.33)	(0.42)	(0.39)	(0.37)	(0.23)	(0.21)	(0.17)
Revenue per Share	0.29	—	—	—	—	—	—
Basic Weighted Avg Shares	106.8	106.4	104.8	103.3	101.7	90.6	69.5
Diluted Weighted Avg Shares	106.8	106.4	104.8	103.3	101.7	90.6	69.5
Supplemental
EBITDA	—	(47.7)	(47.1)	(44.3)	(24.8)	(16.8)	(10.0)
EBIT	(41.8)	(51.9)	(51.2)	(48.3)	(27.4)	(18.2)	(11.1)

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.